← Back to Calendar

Rocket Pharma Q4 2025 Earnings

Rocket Pharma · $RCKT

Standard Review Earnings

PDUFA Date

March 5, 2026

Time Remaining

19d ago

Review Type

Standard (10 mo)

Indication

Q4 2025 earnings + KRESLADI PDUFA preparation update

Key Notes

Q4 2025 earnings reported ~March 2026. Key catalyst: KRESLADI BLA PDUFA March 28, 2026 for LAD-I gene therapy — would be company's first approved product.

⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

← Back to Full Calendar